Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0345904 (
liver cancer
)
15,188
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Rho GTPases control a wide range of cellular processes and contribute to tumor invasion and metastasis. As a regulator of Rho activity,
ARHGDIA
is aberrantly expressed in several types of tumors and plays different roles in the tumor process. To elucidate the role of
ARHGDIA
in
HCC
, we investigated the patterns of its expression, prognosis and clinical profiles in
HCC
. Functional assays were performed to investigate whether the alteration of
ARHGDIA
has an effect on cell growth, migration and invasion, as well as the status of Rho GTPases. We found that
ARHGDIA
was frequently downregulated in
HCC
and associated with tumor invasion and metastasis. Moreover,
ARHGDIA
was significantly associated with OS and TTR of
HCC
patients. Low level of
ARHGDIA
exhibited a decreased postoperative OS and a shorter TTR compared those with high levels. Functional assays showed that loss of
ARHGDIA
promoted
HCC
cell migration and invasion in vitro and lung metastasis formation in vivo. We found that loss of
ARHGDIA
significantly induced Rac1 and RhoA activation which may contribute to invasion and metastasis of
HCC
. In conclusion, the present study has identified loss of
ARHGDIA
contributed to the processes of hepatic tumorigenesis, in particular invasion and metastasis which may provide a potential therapeutic target for
HCC
.
...
PMID:Loss of ARHGDIA expression is associated with poor prognosis in HCC and promotes invasion and metastasis of HCC cells. 2485 71
